

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehp508@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Supplemental Material

Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of Guinea-Bissau Children

Clara Amalie Gade Timmermann, Kristoffer Jarlov Jensen, Flemming Nielsen, Esben Budtz-Jørgensen, Fiona van der Klis, Christine Stabell Benn, Philippe Grandjean, and Ane Bærent Fisker

Table of Contents

Table S1. Odds ratio for presence of fever, coughing, diarrhea, and any morbidity at inclusion and 9 months with a doubling of serum-PFAS concentrations at inclusion among boys and girls.

Table S2. Percent difference in measles antibody concentrations at inclusion, 9 months, and 2 years with a doubling of serum-PFAS concentrations at inclusion among boys and girls.

Figure S1. Predicted association between PFNA and measles antibody concentrations at inclusion based on the confounder adjusted model including both $\log_{10}(\text{PFNA})$ and $\log_{10}(\text{PFNA})$ squared, excluding highly influential observations ($DFBETA > \frac{2}{\sqrt{N}}$).